Market Place
Sourcing Support
Incyte’s $750M buyout rocked by pause on key trial, asset cull
18 Nov 2024 //
FIERCE BIOTECH
Incyte Completes Acquisition of Escient Pharmaceuticals
30 May 2024 //
BUSINESSWIRE
Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists
24 Apr 2024 //
PRESS RELEASE
Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262
28 Nov 2023 //
BUSINESSWIRE
Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262
12 Oct 2023 //
BUSINESSWIRE
Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262
25 Sep 2023 //
BUSINESSWIRE
Escient Pharmaceuticals Announces Positive Results from Phase 1 Study of EP262
20 Jun 2023 //
BUSINESSWIRE
Escient Announces Presentation of Data Demonstrating Efficacy of EP262
08 Jun 2023 //
BUSINESSWIRE
Escient Announces Presentation of Data Demonstrating Efficacy of EP262
16 Mar 2023 //
BUSINESSWIRE
Escient Announces Presentation of Data Highlighting the Pharmacology of EP262
27 Feb 2023 //
BUSINESSWIRE
FDA clears Escient’s IND for mast cell mediated disorders therapy trial
31 Jan 2023 //
CLINICAL TRIALS ARENA
Escient Announces IND Clearance by FDA to Start Phase 1 Study of EP262
30 Jan 2023 //
BUSINESSWIRE
Escient Announces Presentation of Data Highlighting the Development of EP262
07 Dec 2022 //
BUSINESSWIRE
Sanofi-backed Escient bags $120M series C
28 Nov 2022 //
FIERCEBIOTECH
Escient Pharmaceuticals Announces $120 Million Series C Financing
28 Nov 2022 //
BUSINESSWIRE
Escient Pharmaceuticals Initiates Phase 2 PACIFIC Study Evaluating EP547
17 Nov 2022 //
BUSINESSWIRE
Escient Pharmaceuticals Strengthens Leadership Team with Key New Hires
16 Nov 2022 //
BUSINESSWIRE
Escient Pharmaceuticals Appoints Joshua Grass, MBA as CEO
05 Jan 2022 //
BUSINESSWIRE
Escient PharmaAnnounces Data Presentations Highlighting the Preclinical
04 Nov 2021 //
BUSINESSWIRE
Escient Pharmaceuticals Announces Positive Results from Phase 1 Study of EP547
14 Jul 2021 //
BUSINESS WIRE
Escient Pharmaceuticals Announces Positive Results from Phase 1 Study of EP547
14 Jul 2021 //
BUSINESS WIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.